Jim Simons
BCRX icon

Jim Simons’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jim Simons’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.4M Sell
776,990
-1,351,831
-64% -$10.5M 0.01% 1142
2025
Q4 		$16.6M Sell
2,128,821
-11,713
-0.5% -$84.7K 0.03% 694
2025
Q3 		$16.2M Sell
2,140,534
-386,200
-15% -$3.22M 0.02% 836
2025
Q2 		$22.6M Buy
2,526,734
+1,921,516
+317% +$17.9M 0.03% 651
2025
Q1 		$4.54M Buy
605,218
+60,197
+11% +$486K 0.01% 1492
2024
Q4 		$4.1M Sell
545,021
-44,059
-7% -$334K 0.01% 1576
2024
Q3 		$4.48M Sell
589,080
-371,100
-39% -$2.82M 0.01% 1517
2024
Q2 		$5.93M Sell
960,180
-630,200
-40% -$3.48M 0.01% 1199
2024
Q1 		$8.08M Sell
1,590,380
-164,600
-9% -$926K 0.01% 1113
2023
Q4 		$10.5M Buy
1,754,980
+1,553,135
+769% +$9M 0.02% 922
2023
Q3 		$1.43M Buy
+201,845
New +$1.45M ﹤0.01% 2065
2022
Q4 		– Sell
-565,380
Closed -$7.12M – 4115
2022
Q3 		$7.12M Buy
565,380
+438,900
+347% +$5.65M 0.01% 1217
2022
Q2 		$1.34M Sell
126,480
-125,000
-50% -$1.29M ﹤0.01% 2507
2022
Q1 		$4.09M Buy
+251,480
New +$4.03M ﹤0.01% 1739
2021
Q4 		– Sell
-408,180
Closed -$5.87M – 3894
2021
Q3 		$5.87M Sell
408,180
-624,300
-60% -$9.85M 0.01% 1361
2021
Q2 		$16.3M Buy
1,032,480
+965,010
+1,430% +$13.1M 0.02% 868
2021
Q1 		$686K Sell
67,470
-1,212,910
-95% -$12.5M ﹤0.01% 2785
2020
Q4 		$9.54M Buy
+1,280,380
New +$6.6M 0.01% 1202
2020
Q1 		– Sell
-840,734
Closed -$2.9M – 3441
2019
Q4 		$2.9M Buy
840,734
+629,919
+299% +$1.58M ﹤0.01% 2140
2019
Q3 		$604K Buy
+210,815
New +$656K ﹤0.01% 2802
2018
Q4 		– Sell
-217,203
Closed -$1.66M – 3374
2018
Q3 		$1.66M Sell
217,203
-177,378
-45% -$1.19M ﹤0.01% 2368
2018
Q2 		$2.26M Sell
394,581
-373,222
-49% -$2.05M ﹤0.01% 2204
2018
Q1 		$3.66M Buy
767,803
+371,600
+94% +$1.91M ﹤0.01% 2015
2017
Q4 		$1.95M Buy
396,203
+169,700
+75% +$822K ﹤0.01% 2364
2017
Q3 		$1.19M Sell
226,503
-178,000
-44% -$911K ﹤0.01% 2511
2017
Q2 		$2.25M Buy
404,503
+185,300
+85% +$1.13M ﹤0.01% 2201
2017
Q1 		$1.84M Buy
219,203
+169,300
+339% +$1.18M ﹤0.01% 2285
2016
Q4 		$316K Buy
+49,903
New +$260K ﹤0.01% 2895
2016
Q2 		– Sell
-292,221
Closed -$827K – 3325
2016
Q1 		$827K Buy
292,221
+149,318
+104% +$662K ﹤0.01% 2670
2015
Q4 		$1.48M Buy
+142,903
New +$1.42M ﹤0.01% 2290
2015
Q2 		– Sell
-32,403
Closed -$293K – 3221
2015
Q1 		$293K Buy
+32,403
New +$335K ﹤0.01% 2773
2014
Q2 		– Sell
-90,514
Closed -$958K – 2780
2014
Q1 		$958K Buy
+90,514
New +$965K ﹤0.01% 2103

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jim Simons's BCRX Position: Q1 2026 in Review

Jim Simons reduced its BioCryst Pharmaceuticals (BCRX) stake by 64% in Q1 2026, selling an estimated $10.5M and leaving 776,990 shares worth $7.4M. The position accounts for 0.01% of the portfolio, ranked #1142.

Jim Simons first reported a position in BCRX in Q1 2014 and has held it in 32 quarters since. The position peaked at $22.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jim Simons held 776,990 shares of BioCryst Pharmaceuticals worth $7.4M as of Q1 2026.
  • Jim Simons sold 1,351,831 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $10.5M.
  • BioCryst Pharmaceuticals made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1142 holding.
  • Jim Simons first reported a position in BioCryst Pharmaceuticals in Q1 2014 and has held it in 32 quarters since.
  • Jim Simons's BioCryst Pharmaceuticals position peaked at $22.6M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.